397,634 Shares in Organon & Co. (NYSE:OGN) Purchased by Easterly Investment Partners LLC

Easterly Investment Partners LLC acquired a new position in Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 397,634 shares of the company’s stock, valued at approximately $5,933,000.

Several other large investors have also modified their holdings of the business. Natixis Advisors LLC boosted its holdings in Organon & Co. by 7.9% during the 3rd quarter. Natixis Advisors LLC now owns 48,215 shares of the company’s stock valued at $922,000 after acquiring an additional 3,520 shares during the period. Commerce Bank lifted its position in shares of Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after purchasing an additional 637 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after purchasing an additional 875,128 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Organon & Co. in the third quarter worth about $649,000. Finally, Hancock Whitney Corp lifted its holdings in Organon & Co. by 10.9% during the 3rd quarter. Hancock Whitney Corp now owns 47,182 shares of the company’s stock valued at $903,000 after buying an additional 4,637 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 0.1 %

Shares of NYSE:OGN opened at $14.71 on Thursday. The company has a market capitalization of $3.79 billion, a PE ratio of 4.42, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The business’s fifty day simple moving average is $15.39 and its 200-day simple moving average is $16.31.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.62%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OGN shares. Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.